Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) is a rare and serious adverse event of the yellow fever (YF) vaccine that mimics wild-type YF. Research shows there may be an increased risk of YEL-AVD among the elderly population (≥ 60-65 years old), however this research has yet to be accumulated and reviewed in order to make policy recommendations to countries currently administering the YF vaccine. This paper systematically reviewed all information available on YEL-AVD to determine if there is an increased risk among the elderly, for both travelers and endemic populations. Age-specific reporting rates (RRs) were re-calculated from the literature using the Brighton Collaboration case definition for YEL-AVD and were then analyzed to determine if there was a significant difference between the RRs of younger and older age groups. Two out of the five studies found a significantly higher rate of YEL-AVD among the elderly population. Our findings suggest unexposed elders may be at an increased risk of developing YEF-AVD, however the evidence remains limited. Therefore, our findings for YF vaccination of elderly populations support the recommendations made by the Strategic Advisory Group of Experts (SAGE) in their April 2013 meeting, mainly vaccination of the elderly should be based on a careful risk-benefit analysis.
University of Saskatchewan, Saskatoon, Saskatchewan S7 N 5A2, Canada. Electronic address: err593@mail.usask.ca.
Ellen
E
Rafferty
Philippe
P
Duclos
Sergio
S
Yactayo
Melanie
M
Schuster
D000367:Age Factors; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D012307:Risk Factors; D014611:Vaccination / Q000009:adverse effects*; D022341:Yellow Fever Vaccine / Q000009:adverse effects*
D022341:Yellow Fever Vaccine
AEFI; AVD; Adverse event; Elderly; RR; RRR; Viscerotropic disease; YEL-AVD; YF; YFWG; Yellow fever; Yellow fever vaccine; adverse events following immunization; reporting rate ratios; reporting rates; serious AEFI; serious adverse events following immunization; viscerotropic disease; yellow fever; yellow fever vaccine safety working group; yellow fever vaccine-associated viscerotropic disease